Individual clinical trials and meta-analyses have suggested modest benefit from some antipsychotic agents over placebo for the treatment of psychosis and aggression in patients with dementia
1-3 and that these symptoms may return when a medication is discontinued.
4 Potential harms anticipated with use of these medications include known adverse effects such as metabolic changes and extrapyramidal symptoms.
1,5,6 However, evidence pooled across randomized, placebo-controlled trials (RCTs) of atypical antipsychotics, such as risperidone and olanzapine, demonstrated an increased risk of cerebrovascular adverse events for which the US Food and Drug Administration (FDA) issued a warning in 2003.
7 Subsequent analyses of published and unpublished clinical trial data on atypical antipsychotics by the FDA and a meta-analysis of 15 RCTs by Schneider et al
8 demonstrated an increased mortality risk. In April 2005, the FDA
9 issued a black box warning that the use of atypical antipsychotics leads to increased all-cause mortality when used for behavioral disturbances in patients with dementia. Additional observational analyses
10,11 have demonstrated that first-generation antipsychotic agents confer an even higher mortality risk than do the atypical agents, leading to another FDA
12 black box warning in 2008. However, at the time the warnings were issued, the available evidence described class-wide effects on mortality without clear delineation of the risks associated with individual medications.